%0 Journal Article %A Hans Bisgaard %A Dan Lythgoe %A Carin Jorup %T Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma %D 2016 %R 10.1183/13993003.congress-2016.PA4903 %J European Respiratory Journal %P PA4903 %V 48 %N suppl 60 %X BACKGROUND: Adolescent patients with asthma are not thought to differ from adults in terms of clinical treatment efficacy.AIM AND OBJECTIVE: This analysis of 6 double-blind studies (6–12 months) assessed the efficacy/safety of budesonide/formoterol (BUD/FORM) maintenance and reliever therapy (MART) in adolescent patients (12–17 yrs) with asthma.METHODS: BUD/FORM MART was compared with active comparators (Figure) for time to first severe exacerbation (primary endpoint, except STEAM) and other efficacy parameters. Severe exacerbations were defined as hospitalisation/emergency treatment due to asthma worsening and need for oral steroids for asthma. Safety was assessed by adverse event (AE) type/incidence.RESULTS: Overall, 1845 adolescent patients were included in the individual study efficacy population. BUD/FORM MART was similar to, or more effective than, comparators across all studies for time to first severe exacerbation, with comparable outcomes for adolescents and adults (Figure). Adult/adolescent patients using BUD/FORM MART received a lower mean daily dose of inhaled corticosteroid versus comparators, when study design allowed. AE type/incidence were similar for adults and adolescents on BUD/FORM MART versus comparators across studies.CONCLUSIONS: The efficacy and safety of BUD/FORM MART in adolescent asthma patients is similar to that in adults.FUNDING: AstraZeneca %U